Fulgent Genetics (FLGT) President/COO sells shares for tax withholding

Rhea-AI Filing Summary

Fulgent Genetics (FLGT) insider sale by President & COO: On 08/27/2025, reporting person Xie Jian sold 1,199 shares of Fulgent common stock at a weighted-average price of $21.4847 to satisfy tax withholding from restricted stock units that vested from a Feb 26, 2024 RSU grant. After the sale, Mr. Xie beneficially owns 365,249 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust (where he serves on the investment committee and disclaims beneficial interest except for any pecuniary interest). The Form 4 reports the sale as a routine, nondiscretionary transaction to cover tax obligations rather than an open-market cash-raising sale.

Positive

• Sale was for tax withholding on vested RSUs, indicating a non-discretionary, administrative reason for the transaction rather than a targeted cash sale.
• Significant residual ownership retained: 365,249 shares directly and 220,816 shares indirectly, showing continued substantial alignment with shareholders.

Negative

• None.

Insights

Financial Analyst

TL;DR: Routine RSU tax-withholding sale; small relative impact on insider stake and company float.

The sale of 1,199 shares at a weighted-average price of $21.4847 was executed to satisfy tax withholding associated with vested RSUs from a prior grant. Compared with the combined reported beneficial ownership of 586,065 shares (365,249 direct plus 220,816 indirect), the disposed amount is immaterial and unlikely to change market perception or signal major insider-led liquidity. No options, derivative exercises, or additional compensatory grants are reported here; this appears strictly administrative.

Corporate Governance Expert

TL;DR: Transaction consistent with common tax-withholding practice; governance disclosure is complete and standard.

The Form 4 explains that shares were sold to cover tax obligations from vested restricted stock units, and it identifies the indirect holdings via a family trust where the reporting person serves on the investment committee. The reporting person disclaims beneficial interest except for pecuniary interest, which is appropriately disclosed. The description and price range disclosure meet typical SEC Form 4 transparency expectations.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Xie Jian

(Last) (First) (Middle)

C/O FULGENT GENETICS, INC.

4399 SANTA ANITA AVENUE

(Street)

EL MONTE CA 91731

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Fulgent Genetics, Inc. [ FLGT ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President and COO

3. Date of Earliest Transaction (Month/Day/Year)
08/27/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	08/27/2025		S		1,199(1)	D	$21.4847(2)	365,249	D
Common Stock								220,816	I	By Trust(3)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The shares were sold by the reporting person to satisfy the tax withholding obligations that arose upon the vesting of certain restricted stock units granted to the reporting person on February 26, 2024, which grant was originally reported on Form 4 filed with the U.S. Securities and Exchange Commission on February 28, 2024.

2. The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66, inclusive. The reported price reflects the weighted-average sale price. The reporting person hereby undertakes to provide upon request to the Securities and Exchange Commission staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected.

3. Securities held by The Hsieh Family Dynasty Trust, dated January 27, 2010 (the "Trust"). Mr. Xie serves on the investment committee of the Trust. Mr. Xie disclaims any beneficial interest except with respect to any pecuniary interest therein.

	/s/ Paul Kim as Attorney-in-Fact	08/28/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did FLGT insider Xie Jian do on 08/27/2025?

Mr. Xie sold 1,199 shares of Fulgent common stock on 08/27/2025 at a weighted-average price of $21.4847.

Why were the shares sold by the FLGT reporting person?

The shares were sold to satisfy tax withholding obligations arising upon the vesting of restricted stock units granted on February 26, 2024.

How many FLGT shares does Xie Jian own after the reported transaction?

Following the transaction, Mr. Xie beneficially owns 365,249 shares directly and 220,816 shares indirectly through The Hsieh Family Dynasty Trust.

What price range were the sold FLGT shares executed at?

The shares were sold in multiple transactions at prices ranging from $21.28 to $21.66; the Form 4 reports the weighted-average sale price as $21.4847.

Does Mr. Xie have any role with the trust that holds indirect FLGT shares?

Yes. The indirect holdings are held by The Hsieh Family Dynasty Trust dated January 27, 2010; Mr. Xie serves on the trust's investment committee and disclaims beneficial interest except for any pecuniary interest.